Allianz Asset Management
SYRE icon

Allianz Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Allianz Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
+14,100
New +$1.03M ﹤0.01% 1848
2024
Q2 		– Sell
-31,800
Closed -$1.21M – 2251
2024
Q1 		$1.21M Buy
+31,800
New +$921K ﹤0.01% 1358

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Allianz Asset Management's SYRE Position: Q2 2026 in Review

Allianz Asset Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 14,100 shares worth $1.25M. The stake represents ﹤0.01% of the portfolio and ranks #1848 among its holdings. This is a return to the name: Allianz Asset Management previously reported a position in SYRE as recently as Q1 2024.

Allianz Asset Management first reported a position in SYRE in Q1 2024 and has held it in 2 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Allianz Asset Management held 14,100 shares of Spyre Therapeutics worth $1.25M as of Q2 2026.
  • Spyre Therapeutics was a new Allianz Asset Management position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1848 holding.
  • Allianz Asset Management first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.